Health Bulletin 29/December/2021

Here are Top Health stories of the day

Resident doctors to continue stir as talks with Mandaviya fail

Resident doctors in Delhi, who have been protesting over the delay in NEET-PG 2021 counselling for the past 12 days, on Tuesday decided to continue the stir, as a meeting between their federation's delegation and the Union health minister failed to make any headway.

The meeting between a delegation of the Federation of Resident Doctors' Association (FORDA) and Union Health Minister Mansukh Mandaviya took place at Nirman Bhawan here, but the doctors' body said, the "response was not satisfactory".

For more details, check out the full story on the link below:

Resident Doctors To Continue Stir As Talks With Mandaviya Fail

MCC NEET counselling 2021

Mediclaim cannot be rejected citing existing illness: SC

An insurer cannot repudiate a claim by citing an existing medical condition that was disclosed by the insured in the proposal form, once the policy has been issued, the Supreme Court has said.

A bench of justices D Y Chandrachud and B V Nagarathna also said a proposer is under a duty to disclose to the insurer all material facts within his knowledge.

For more details, check out the full story on the link below:

Mediclaim Cannot Be Rejected Citing Existing Illness: SC

Granules India secures USFDA nod for Prazosin Hydrochloride Capsules

Granules India Limited announced that the US Food & Drug Administration (USFDA) has approved the Abbreviated New Drug Application (ANDA) filed by Granules Pharmaceuticals, Inc. (GPI), a wholly owned foreign subsidiary of Granules India Limited, for Prazosin Hydrochloride Capsules, USP 1mg, 2mg & 5mg.

It is bioequivalent to the reference listed drug product (RLD), Mini plus capsules 1Mg, 2Mg & 5 Mg of Pfizer Inc. The product would be available for the US market shortly.

For more details, check out the full story on the link below:

Granules India Secures USFDA Nod For Prazosin Hydrochloride Capsules

Yellow alert in National capital